IPA to Present at The Microcap Conference 2025
ImmunoPrecise Antibodies (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, has announced its participation in The Microcap Conference 2025. The event will be held from January 28-30, 2025, in Atlantic City, NJ. During the conference, IPA's management team will deliver a corporate presentation and conduct one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities.
ImmunoPrecise Antibodies (NASDAQ:IPA), un'azienda di ricerca e tecnologia bioterapeutica guidata dall'IA, ha annunciato la sua partecipazione a The Microcap Conference 2025. L'evento si terrà dal 28 al 30 gennaio 2025, ad Atlantic City, NJ. Durante la conferenza, il team di gestione di IPA presenterà un intervento aziendale e condurrà incontri one-to-one con investitori istituzionali e individuali per discutere degli sviluppi recenti della società, della strategia di crescita e delle opportunità di investimento.
ImmunoPrecise Antibodies (NASDAQ:IPA), una empresa de investigación y tecnología bioterapéutica impulsada por IA, ha anunciado su participación en The Microcap Conference 2025. El evento se llevará a cabo del 28 al 30 de enero de 2025 en Atlantic City, NJ. Durante la conferencia, el equipo de gestión de IPA realizará una presentación corporativa y llevará a cabo reuniones individuales con inversionistas institucionales y particulares para discutir los desarrollos recientes de la empresa, su estrategia de crecimiento y las oportunidades de inversión.
ImmunoPrecise Antibodies (NASDAQ:IPA), AI 기반의 생물 의약품 연구 및 기술 회사가 The Microcap Conference 2025에 참여한다고 발표했습니다. 이 행사는 2025년 1월 28일부터 30일까지 뉴저지주 애틀랜틱 시티에서 열릴 예정입니다. 컨퍼런스 동안 IPA의 경영진 팀은 기업 발표를 진행하고 기관 및 개인 투자자들과 개별 회의를 통해 회사의 최근 발전, 성장 전략 및 투자 기회를 논의할 것입니다.
ImmunoPrecise Antibodies (NASDAQ:IPA), une entreprise de recherche et de technologie biothérapeutique alimentée par l'IA, a annoncé sa participation à The Microcap Conference 2025. L'événement se déroulera du 28 au 30 janvier 2025 à Atlantic City, NJ. Pendant la conférence, l'équipe de direction d'IPA fera une présentation d'entreprise et conduira des réunions en tête-à-tête avec des investisseurs institutionnels et individuels pour discuter des récents développements de la société, de sa stratégie de croissance et des opportunités d'investissement.
ImmunoPrecise Antibodies (NASDAQ:IPA), ein KI-gestütztes Unternehmen für biotherapeutische Forschung und Technologie, hat seine Teilnahme an The Microcap Conference 2025 bekannt gegeben. Die Veranstaltung findet vom 28. bis 30. Januar 2025 in Atlantic City, NJ, statt. Während der Konferenz wird das Führungsteam von IPA eine Unternehmenspräsentation halten und Einzelgespräche mit institutionellen und privaten Investoren führen, um über die jüngsten Entwicklungen des Unternehmens, die Wachstumsstrategie und Investmentmöglichkeiten zu diskutieren.
- None.
- None.
VICTORIA, BC / ACCESSWIRE / December 19, 2024 / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today announced is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, in Atlantic City, NJ.
IPA's management team will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities.
About The Microcap Conference 2025
The Microcap Conference is the largest independent microcap event in the U.S., bringing together top-tier investors and executives from microcap companies. The event offers a platform for companies to showcase their value propositions through presentations, one-on-one meetings, and networking opportunities.
The 2025 event will feature:
Keynote Speakers: Renowned industry figures, including Jon Ledecky, Co-Owner of the New York Islanders, who will engage in a fireside chat with CNBC's Bob Pisani; plus Tom Gardner, CEO of Motley Fool, who will share insights on investing, market trends, and entrepreneurial success.
Expert Panels and Presentations: Financial commentators Ron Insana (CNBC) and Charlie Gasparino (FOX Business) will cover critical topics for the US equity markets, from capital formation to regulatory updates and market trends.
Entertainment Headliner: A special performance by Tom Papa, celebrated comedian and host of Netflix specials, ensuring a memorable evening for attendees.
Hosted by DealFlow Events, The Microcap Conference is renowned for its blend of high-quality content, engaging networking, and exceptional entertainment. For more information, visit https://themicrocapconference.com.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and is known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the "IPA Family").
Investor Relations Contact
SOURCE: ImmunoPrecise Antibodies Ltd.
View the original press release on accesswire.com
FAQ
When and where is IPA presenting at The Microcap Conference 2025?
What will IPA's management team discuss at The Microcap Conference 2025?
What type of investors will IPA meet at The Microcap Conference 2025?
What is the significance of IPA's participation in The Microcap Conference 2025?
